01 1 Neulasta/Peglasta
02 7G-Lasta
03 9Neulasta
04 6Neulasta/Peglasta
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 2,293
2019 Revenue in Millions : 3,221
Growth (%) : -29
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 253
2019 Revenue in Millions : 233
Growth (%) : 9
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 1,734
2020 Revenue in Millions : 2,293
Growth (%) : -24
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 39
2019 Revenue in Millions : 36
Growth (%) : 8
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 45
2020 Revenue in Millions : 39
Growth (%) : 29
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 248
2020 Revenue in Millions : 253
Growth (%) : 10
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 235
2021 Revenue in Millions : 248
Growth (%) : -5
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 1,126
2021 Revenue in Millions : 1,734
Growth (%) : -35
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 42
2021 Revenue in Millions : 45
Growth (%) : -5
Main Therapeutic Indication : Hematology
Currency : USD
2023 Revenue in Millions : 215
2022 Revenue in Millions : 235
Growth (%) : 3
LOOKING FOR A SUPPLIER?
